Chen, H., Hu, H., Shen, C., Qie, Y., Wu, Z., Bai, Y., Zhang, Z., Huang, S., Jia, K., Li, P., Lin, Y., Xue, Z. (2025). Neoadjuvant tislelizumab combined with disitamab vedotin (RC48) for patients with Her-2 expressing upper tract urothelial carcinoma: A pilot study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e16588